These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Please note that the physiological activity of the ingredient(s) described herein is supported by the referenced clinical trial reports. Marketers of finished products containing the ingredient(s) described herein are responsible for determining whether claims made for such products are lawful and in compliance with the laws of the country in which they will market the products.



  • Filter Research By Type:

  • Filter Research By Dosage:

Don’t see what you’re looking for? All additional research is categorized under supportive research.

Pharmacokinetics of solid lipid Boswellia serrata particles [WokVel® SLP] in healthy subjects.

Kulkarni PD et al.
Drug Metabol Personal Ther. 05 Apr 2021. 0(0). doi: 10.1515/dmdi-2020-0176
The anti-inflammatory activity of Boswellia serrata extracts (BSE) is well known. BSE comprises boswellic acids (BA) such as 3-O-acetyl-11-keto-beta-boswellic acid (AKBA) and 11-keto-boswellic acid (KBA) as major constituents. One of the limitations of BAs is their poor oral bioavailability. The aim of the study was to prepare solid lipid particles of Boswellia serrata extract (SLBSP) to enhance the bioavailability of BAs.

Double-blind trial of solid lipid Boswellia serrata particles (SLBSP) [WokVel® SLP] vs. standardized Boswellia serrata gum extract (BSE) [WokVel®] for OA of knee.

Kulkarni PD et al.
Drug Metabol Personal Ther. 08 Jun 2020. 35(2). doi: 10.1515/dmpt-2020-0104
The present study was planned to investigate the efficacy of SLBSP vs. standardized BSE for symptomatic knee osteoarthritis (OA) treatment. Methods It was a prospective, randomized, double-blind, double-dummy, placebo-controlled, and single-centre clinical trial for symptomatic osteoarthritis of knee.

Comparison of the metabolic stability of solid lipid Boswellia serrata particles [WokVel® SLP] versus plain Boswellia serrata extract [WokVel®] in human hepatocytes (HHL-17).

Gota P et al.
Int J Pharm Chem Biol Sci. 2016. 6(1): 22-27.
In an in vitro study in human hepatocytes HHL-17, WokVel® SLP™ (Solid Lipid Particle) exhibited lesser accumulation of KBA in hepatocytes and low metabolic clearance. With reported extremely low hepatic clearance of AKBA and conferred metabolic stability of KBA in this study, WokVel® SLP™ may have enhanced oral bioavailability of KBA and AKBA compared to WokVel.

Efficacy of solid lipid Boswellia serrata particles (SLBSP) in OA of knee.

Gota P et al.
J Pharm Sci Tech Mgmt. 2015 Jul. 1(2): 70-76.
Patients with osteoarthritis were treated with solid lipid Boswellia serrata particles (SLBSP – WokVel® SLP) capusles for two months. There was significant improvement in pain and function scores of the WOMAC and VAS indices, and the need for rescue analgesics was markedly decreased by 67% during the first month and 76% during the second, compared to baseline.

Prospects of boswellic acids as potential pharmaceutics.

Du Z et al.
Planta Med. 2015. 81(04): 259-271. doi: 10.1055/s-0034-1396313
A comprehensive review on boswellic acids and their potential for clinical applications; bioavailability, different derivatives, and bioavailability enhancement is discussed.

Effect of Boswellia serrata extract [WokVel®] on degenerative OA in in-vitro and in-vivo models.

Nam DE et al.
J Korean Soc Food Sci Nutr. 2014 Apr 2. 43(5). doi: 10.3746/jkfn.2014.43.5.페이지
WokVel® Extract mediated articular cartilage degeneration by preventing extracellular matrix degradation and chondrocyte injury. It significantly reduced and normalized the production of pro-inflammatory biomarkers and also significantly reduced 5-LOX activity and production of PEG2. Researchers indicated that, “one can consider that [WokVel®] extract may be a potential therapeutic treatment for degenerative [OA].”